Mediomics公司2001年成立，致力于为学术机构、制药公司、医学研究者、环境研究者提供创新性的检测试剂盒及生物感应物质。Mediomics拥有Patented Bridge-It® Assay Platform、Patented FRET-PINCER® Assay Platform、Patented TRF-PINCER® Assay Platform三大技术平台。

Mediomics, LLC provides innovative assay kits and biosensors needed by academic research laboratories, point of care testing, pharmaceutical companies, as well as medical and environmental research markets.  

Technology platforms:

（1）Patented Bridge-It® Assay Platform

Bridge-It® Assays are optimized to measure DNA binding proteins, their ligands, and co-regulators. Mediomics’ Bridge-It® assay was based on a simple idea of splitting the DNA binding site for a protein into two DNA half-sites. The presence of the DNA-binding protein or one of its ligands can be detected by FRET (fluorescence resonance energy transfer).

（2）Patented FRET-PINCER® Assay Platform

FRET-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected FRET-PINCER® Assay system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light through FRET (fluorescence resonance energy transfer).

（3）Patented TRF-PINCER® Assay Platform

TRF-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected TRF-PINCER® Assay platform system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light with Time-Resolved Fluorometry (TRF) sensitivity.

主要产品线包括：

（1）Bridge-It® Assay

（2）TR-FRET Bridge-It® Assay

（3）FRET-PINCER® Assay

（4）TR-FRET PINCER®Assay

（5）Other

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技代理Innovative Biochips品牌全系列产品

Innovative Biochips是休斯顿德克萨斯医学中心（TMC）的衍生公司，专注于开发先进的微流控技术，以尖端的灵敏度和高通量解决传统生物技术面临的难题。科研团队和工程师在为各类生物和生物医学应用开发新型微流体技术方面积累了的经验。通过不断创新和优化技术，Innovative Biochips为生命科学研究提供了更精准的工具，推动生物医学领域的进步。主要产品包括单细胞克隆分析、单细胞成像和配对、球状细胞培养等。

▍Innovative Biochips公司产品线

● 单细胞PCR与测序技术：本系列产品融合标准设备制式与创新微流控设计，提供多种简易、快速、经济的单细胞分离方案：实现单细胞向超微量液体环境的高效转移；完美适配单细胞裂解、PCR及测序等遗传分析流程。

● 单细胞克隆：在重组蛋白生产、基因功能研究与药物筛选中应用广泛。1CellPlate®-96孔超微量微流控板采用标准96孔板规格，结合独特的"孔中孔"微流控设计，为癌细胞、杂交瘤细胞、CHO细胞、CRISPR编辑细胞及干细胞等稳定细胞株开发，提供前所未有的简易单细胞分离方案。

● 单细胞检测：1CellPlate®-Assay 超低体积 96 孔微流控微孔板结合了超小孔和微流控网络，满足了单细胞细胞因子检测的需求。单细胞分泌的细胞因子可被收集并通过质谱进行深度分析。此外，具有显著高细胞因子分泌量的单细胞，也能通过常规移液器轻松回收，用于包括克隆或 PCR 测序在内的下游分析。

● 自动化寿命检测：自动解剖芯片 (AD-Chip) 结合延时显微技术，可在 3 天内对 20 种不同菌株的逾万个单酵母细胞进行自动化全寿命追踪。该芯片能够在整个衰老过程中对单细胞进行高分辨率荧光成像。

▍Innovative Biochips产品列表

Allele Biotechnology位于美国圣地亚哥市，主要专注于对生物过程的机制进行探索，以开发生物医学及治疗相关的技术和产品。以各个物种的iPS细胞、人类cGMP iPS细胞及衍生的细胞为材料，Allele Biotechnology利用专利性的非整合细胞编辑方法，开发了出了细胞治疗和药物筛选的技术。Allele Biotechnology具有深厚的基因组修饰和细胞荧光报告因子的经验，为客户提供优异的细胞检测解决方案。Allele Biotechnology还提供荧光蛋白、高效荧光素酶底物、基因分型试剂盒、骆驼抗体等产品；此外还在RNA干扰领域尤其独特的专利。

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.

Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge technologies in individual products and fully integrated platforms. Allele utilizes proprietary non-integrating cellular reprogramming methods to develop cell therapy and enable drug discovery through the use of human and non-human primate iPS cells, cGMP-grade human iPS cells and their derivatives. With additional expertise in genome modification and unique cell-based fluorescence sensors/reporters, Allele provides advanced cell and assay development solutions. Allele also has developed a wide variety of advanced research tools including superior fluorescent proteins, highly efficient luciferase assay substrates, genotyping kits, and camelid antibodies that have been validated for co-immunoprecipitation, histology, and flow cytometry. The Company has also been a leader in the RNAi field with its patents in Pol III promoter-driven siRNA, shRNA, and miRNA.